8 Million Units in Japan, Not Sold in Korea

What is the signal?

According to Seoul Economic Daily reports on 3 and 4 November, several K-beauty brands run product lines that can only be bought in Japan. Anua, operated by The Founders, sells an eight-item Japan-only azelaic acid line; made up of serums, toners and lotions, its cumulative sales have passed 8 million units in Japan alone. Its flagship, the Azelaic Acid 15 Intense Calming Serum, is not sold in Korea, and is known as a product Korean tourists buy in Japan and bring back.

APR uses the same approach. It introduced an azelaic acid and niacinamide line in Japan in February 2025, followed by a placenta and ceramide line that December and a glycylglycine line in late May 2026. All are reported as Japan-only products that have either not been released in Korea and other markets or have no separate launch planned. d'Alba formally launched the White Truffle First Spray Serum Peptide Osmanthus in July 2026, sold only in Japan, and runs country-specific products in major overseas markets including Japan and Russia.

In one case the format itself was created from scratch. News1 reported that APR developed the first milky lotion in the Medicube brand's history in response to requests from Japanese consumers. It was built separately for the local habit of using a toner and a milky lotion together; the product is the Glycylglycine Ceramide Barrier Emulsion, and sales began through Qoo10. It adds a moisturising step to the existing toner and serum line. The same article gave Japan's imports of Korean cosmetics in the first half of 2026 as ¥82.1 billion, offering it as the backdrop to this expansion of market-exclusive products.

One product moved the other way. APR's Ribbon Cherry Glass Hair Brush passed 100,000 cumulative units in Japan within two months, and subsequently entered Korean duty-free shops and the Chinese market. An exclusive product is not permanently tied to one market: a route has emerged in which an item proven in Japan later crosses into others.

A note on scope. The sales figures and launch dates here come from trade reporting that cites industry sources and company disclosures, not from independently audited counts. The Seoul Economic Daily reports attribute their figures to industry sources, so individual numbers are best read as company-reported. The brands named here are also mid-to-large players that already hold distribution and local organisations in Japan; the reporting gives no basis for assuming the same strategy transfers to a brand exporting for the first time. The judgement points below set out the development conditions these cases share, and regulatory figures such as ingredient concentration limits or labelling requirements need separate local confirmation per item.

1. This is building new SKUs, not picking what to export

The standard form of export planning until now has been selection: take items already proven at home, pick those that can clear local regulation, and ship them with the label and declarations changed. The advantages are clear. The formula is already fixed, the production run can be combined with domestic volume, and if the response is poor you simply reduce that one market.

The reported cases sit on the opposite side. Anua's Japan-only line runs to eight items, and APR released three consecutive lines in Japan alone between 2025 and 2026. That no equivalent product exists in Korea means the entire production volume of that formula depends on demand in a single market. This is exclusive development rather than selection, and so the decisions change.

The first is line breadth: whether the exclusive product goes out as a single item or as a line. The reported Anua line runs to eight items including serums, toners and lotions, while Medicube's milky lotion adds one step to an existing toner and serum line. The first builds a whole line from scratch; the second attaches one item to a line that already exists. The development burden and the inventory risk are entirely different.

The second decision is how far the shared bulk reaches. An exclusive line does not require every item's formula to be exclusive. Items where the base makes up most of the product, such as toners and lotions, can run on existing bulk while only the serum carrying the hero ingredient is designed as exclusive. Settle where the shared boundary falls and the scope of exclusive development is settled, which in turn shows how many separate formulas each need to clear a minimum production quantity.

The third is writing non-release at home into the document. "Not launching in Korea for now" and "no plan to launch in Korea" lead to different development choices. If a domestic launch stays open, the formula and labelling have to suit both markets; if the product is fully exclusive, one market's requirements are enough. Leave that line blank and redevelopment appears later.

• Whether the number of items is written down — single product or full line
• Whether the boundary between exclusive formulas and shared bulk is drawn within the line
• Whether the minimum production quantity is calculated per formula
• Whether domestic and third-market launch is recorded as "none" or "on hold"

2. A different routine step means one more format

What the Medicube milky lotion case shows is sequence, not ingredients. The existence of a local habit of using a toner and a milky lotion together became the starting point for development. The toner and serum already in the line left one slot in that sequence empty, and the brand's first-ever milky lotion was made to fill it.

This distinction matters because the empty slot differs by market. Where the step structure in Korea and the step structure in Japan diverge, sending the same line across unchanged reads to the consumer as a line with a gap in the middle. A situation arises in which one more item is needed without any need to change the ingredients.

Translated into development conditions, viscosity and sensory feel come first. A milky lotion has to occupy the band heavier than a toner and lighter than a cream, and it has to layer over and under the neighbouring products without pilling or balling. It is a texture that works inside a particular sequence rather than one that is good in isolation, so sample evaluation should be done by layering in that market's routine order rather than item by item.

Packaging is decided alongside. An item used after a toner is dispensed in larger amounts into the palm, which suits a higher output; one used after a serum suits accurate delivery of a small dose. Where the item sits in the routine sets the dispensing method and the fill volume. Defer that decision until after the formula is locked and the container gets re-selected or the filling specification changed.

One addition: this is about finding the empty slot, not adding slots. In markets moving toward fewer steps the same logic runs in reverse, and an exclusive product that combines two slots into one item may be the answer. Either way, the first thing to write is how many steps that market's routine has and which of them your line already covers.

• Whether the target market's routine steps are written down with your line's coverage marked
• Whether you are filling an empty slot or combining slots
• Whether sample evaluation layers products in that market's order rather than testing items alone
• Whether dispensing method and fill volume were set before the formula was locked

3. The ingredient name sets the line name

List the names of the reported exclusive lines and a pattern appears: azelaic acid, placenta and ceramide, glycylglycine, white truffle and osmanthus. The product names stand on ingredient names rather than concept words. The assumption that consumers in that market search for products by ingredient name is carried directly into the line name.

At the planning stage this means ingredient selection comes before marketing rather than after. Instead of deciding what claim to make and then finding an ingredient to support it, the order is to fix the ingredient name already being searched and discussed in that market, then design a formula in which that ingredient can play the lead. If the product name is the ingredient name, that ingredient cannot be a supporting player in the formula.

Regulatory confirmation follows immediately. The same ingredient may carry different use limits and labelling requirements by market, and putting an ingredient in the product name makes it the subject of claim substantiation in itself. This article gives no concentration limits as figures: the reporting does not contain them, and the concentration explanations circulating on blogs and social media are not primary sources. What belongs in the brief instead is who confirmed, from which document, whether this ingredient can appear in a product name in this market and up to what concentration.

Choosing to put an ingredient name front and centre has a reverse side. If the ingredient name is the product name, the ingredient's reputation becomes the product's reputation. Should regulation on that ingredient change, or preference in that market cool, the whole line name has to be rebuilt. Name it with a concept word instead and you keep room to swap the ingredient, but you are not found in search. Which way to take that trade is settled before the formula.

The d'Alba case shows another axis. White truffle with osmanthus combines a functional ingredient with a scent, and scent is the item where preference splits most sharply by market. An exclusive product that runs the same base formula with a different fragrance is a relatively light form of exclusive development, but whether the fragrance change affects stability and colour has to be checked separately.

• Whether the product name will use an ingredient name or a concept word
• Whether it is confirmed from primary sources that the ingredient may appear in the name and labelling in that market
• Whether the hero ingredient genuinely plays a central role in the formula
• Whether stability and colour effects were assessed where only the fragrance differs

4. An exclusive line splits volume planning in two

The largest variable in an exclusive product is not the formula but the volume. A product shared with the domestic market lets one bulk run flow into several markets; an exclusive one has to be consumed within that market alone. The figure of more than 8 million units for Anua's line in Japan is an outcome. At the planning stage the number to look at first is the opposite one: how many units the first run is cut to.

So volume planning for an exclusive line splits into two layers: a minimum run for validation, and a main production run once response is confirmed. Both numbers need to be set together in advance, because the formula and the packaging specification have to carry both layers. Specify against the first run alone and the unit cost structure fails in main production; specify against main production alone and the first run quantity cannot be met.

COSLAB consults on projects from 1,000 units upward; what is actually feasible depends on the formula, container, raw materials, process and specification. The practically useful point here is the relationship between item count and volume. Build an exclusive line as eight items and the total run multiplies by the item count even if per-item volume is set low. A wide line with low per-item volume and a narrow line with higher per-item volume create entirely different inventory risk.

Packaging is usually the tighter constraint. Some exclusive products only change the label, but building a whole line creates new container and carton specifications. Components often carry higher minimum order quantities than formulas, so the real floor for an exclusive line is frequently set by the container rather than the formula. It is safer to confirm the minimum order quantity for containers and cartons separately before fixing the first run.

Finally, the exit for inventory has to be decided in advance. A shared product can be redirected to another market if one closes; an exclusive product has that route shut. If you are going exclusive, the brief needs an answer to where this stock goes if the response falls short of expectations. Without that answer, the risk of an exclusive product is the whole production volume.

• Whether validation-run and main-run quantities are each written as numbers
• Whether total run volume was calculated as item count multiplied by per-item volume
• Whether container and carton minimum order quantities were confirmed separately from the formula
• Whether an exit for exclusive inventory is defined if response falls short

5. Keep the route back open from the start

The interesting part of these cases is that exclusive products do not stay exclusive. APR's hair brush passed 100,000 cumulative units in Japan within two months, then entered Korean duty-free shops and the Chinese market. Anua's Japan-only serum flows into Korea not through an official route but through purchases by Korean tourists. One is planned expansion; the other is unplanned backflow.

Taking planned expansion first, moving an item proven in one market into another is the most realistic way to recover the cost of exclusive development. For that route to stay open, however, the formula and labelling have to be able to clear the requirements of the market it moves into. Design against one market's requirements from the start and ingredient limits or labelling items may block the transfer, which means redevelopment.

It therefore helps to fix one first-choice expansion market while designing the exclusive line. This does not mean building a formula that fully satisfies both markets; it means deciding where transfer is most likely and at minimum avoiding that market's prohibited and restricted ingredients. That single check is the difference between transferring later with only a labelling change and redeveloping the product.

Unplanned backflow creates a different problem. When a product not sold at home is used domestically through tourist purchases, domestic enquiries and reports of adverse reactions arise without official distribution behind them, because there is no Korean-language usage information and the product sits outside the domestic responsible-distributor structure. Launch an exclusive product without settling where a domestic enquiry about it is routed, and that response starts unprepared.

Price is the other item. Where a brand's product exists in one market and not another, consumers in the two markets lose their reference point for comparison. That is an advantage of an exclusive product and also a burden when expanding later, because the price has to be designed again. Where to place an exclusive product if it is brought home later is worth thinking through once at the time of the exclusive launch.

• Whether one first-choice expansion market is fixed and its restricted ingredients avoided
• Whether transfer would need only a labelling change or full redevelopment
• Whether the route for domestic enquiries about an exclusive product is defined
• Whether the price position for bringing the product home later has been considered

The first question for the brief

Try turning the line that read "for export to Japan" into two. The first says whether this product is exclusive to that market or shared with the domestic range. The reported cases are the result of choosing exclusive, and that choice sits ahead of locking the formula. A shared product means designing against several markets' requirements at once; an exclusive one means meeting a single market's requirements while placing the entire volume risk on that market.

The second thing to write is item count and volume: how many items the exclusive line runs to, how many of those use exclusive formulas and how many run on shared bulk, and how many units the first run and the main run are each cut to. Build the line wide and per-item volume falls, but total run volume and the number of component types rise together. It is worth confirming minimum order quantities for containers and cartons separately from the formula.

The last is one expansion market. Write down where this exclusive product is most likely to go next, and at minimum avoid the ingredients prohibited or restricted there. With that line in place, a proven exclusive product can transfer on a labelling change alone; without it, the same product has to be developed again.